ALESSANDRO Gozzetti

Achievinh at least one MRD negativity during 24 months of daratumumab gave PFS advantage of 61 months vs 26 months

70% of the patients MRD negative at data cut off achieved negativity between month 6 and 24

The #IMS26 preliminary program is now available! View the schedule for Glasgow and register today ➡️ bit.ly/4cdFJkH

30% MRD negativity conversion at 6 months by single agent Daratumumab measured by NGF at 10-6 in a selected population of patients already >vgpr

@VincentRK That is true…plus personally the patient motivates always more than anything

A lot of advances in medicine are driven by individual investigators with a passion to solve a medical problem and improve outcomes. They go above and beyond. Nights, weekends. Barriers. Disappointments. With or without institutional support. They do this despite the fact that they usually don’t gain anything financially, and often make far less money to pursue their passion for research. Their main reward is the progress itself, and that’s sufficient. Yes, some do receive recognition, awards, and fame, but for most of my colleagues that’s not the driver of why they do what they do.

Born in 2017 , first MRD driven trial : at 6 months negative patients stopped treatment while positive continued for two years

MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM buff.ly/IWyPONK

British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…

Our trial on daratumumab the DART4MM is published! MRD negativity at 10-6 byNGF reached and maintained by single agent Daratumumab

Full article: Anti CD38 monoclonal antibodies for multiple myeloma treatment tandfonline.com/doi/full/10.10…

Full article: Anti CD38 monoclonal antibodies for multiple myeloma treatment tandfonline.com/doi/full/10.10…

Anti CD38 monoclonal antibodies for multiple myeloma treatment pubmed.ncbi.nlm.nih.gov/35404740/

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma pubmed.ncbi.nlm.nih.gov/37305387/

American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/aj…

American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/full/10.10…

Good news! My article received enough downloads to be a #TopDownloadedArticle in its journal.

@VincentRK @Rfonsi1 Unfortunately real life is different from clinical trials.. for examole in Italy we have dara vtd for TE mm patients but different from Cassiopeia lenalidomide for maintanance….completely different story…

@Rfonsi1 Ahh. Another obituary.. In many parts of the world — (probably most myeloma patients globally) Dara is not feasible financially. So VRd will be alive and well for a while. But if Dara available, role for VRd is certainly limited. I got some criticism for this 20 years ago!👇

Unless you combine with an anti-CD38 antibody... #EHA24RF #MMSM

💝#HotPaper #mdpijpm📷 ✔️ "Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)" 👨‍💻Vincenzo Sammartano et al. 🧐mdpi.com/2075-4426/12/3…

Great work!honored to be part of it!

Management of multiple myeloma-related renal impairment: recommendatio... sciencedirect.com/science/articl…